BMAL1 and pancreatic neoplasm: To test this hypothesis, we used a syngeneic Kras- and Trp53-mutant pancreas cancer cell line (KPC) and employed CRISPR/Cas9 technology to functionally knockout Bmal1 (KPC-BKO) so that we could examine the effects of clock dysfunction in vitro and in vivo [36].